Icosavax, Inc.
NASDAQ:ICVX
Overview | Financials
Company Name | Icosavax, Inc. |
Symbol | ICVX |
Currency | USD |
Price | 15.31 |
Market Cap | 769,036,610 |
Dividend Yield | 0% |
52-week-range | 4.75 - 16.105 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adam K. Simpson |
Website | https://icosavax.com |
An error occurred while fetching data.
About Icosavax, Inc.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD